High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic Cell Support for Patients With Relapsed/Refractory Hodgkin's Disease.

Trial Profile

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic Cell Support for Patients With Relapsed/Refractory Hodgkin's Disease.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Busulfan (Primary) ; Gemcitabine (Primary) ; Melphalan (Primary) ; Palifermin; Rituximab
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Apr 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Jun 2018.
    • 11 Apr 2016 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2018.
    • 26 Aug 2013 Planned end date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top